US1570851014 - Common Stock
2.21 0 (0%)
After market: 2.24 +0.03 (+1.36%)
NASDAQ:CERS (2/26/2024, 7:24:13 PM)After market: 2.24 +0.03 (+1.36%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 309 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.
1220 Concord Ave Ste 600, 2550 Stanwell Drive
Concord CALIFORNIA 94520
CEO: William M. Greenman
The widely followed growth investor keeps making moves.
Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.
These innovation-oriented companies could take flight this year.
Cerus Corporation reports 6% increase in fourth-quarter product revenue. Full-year unaudited revenue for 2023 expected to be $156.4 million.
Here you can normally see the latest stock twits on CERS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.